Dermira to Report First Quarter 2019 Results and Host Conference Call on Tuesday, May 7, 2019
April 30 2019 - 4:05PM
Business Wire
Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company
dedicated to bringing biotech ingenuity to medical dermatology by
delivering differentiated, new therapies to the millions of people
living with chronic skin conditions, will report financial results
for the quarter ended March 31, 2019 and provide an operational
update after market close on Tuesday, May 7, 2019. The company will
host a conference call and an audio webcast at 1:30 p.m. Pacific
Time (4:30 p.m. Eastern Time) on the same day.
Conference Call Information:
Domestic callers: 1-877-359-9508 International callers:
1-224-357-2393 Passcode: 3485374
Webcast information: Visit http://investors.dermira.com.
A webcast replay will be available on the Dermira website for 30
days.
About Dermira
Dermira is a biopharmaceutical company dedicated to
bringing biotech ingenuity to medical dermatology by delivering
differentiated, new therapies to the millions of patients living
with chronic skin conditions. Dermira is committed to
understanding the needs of both patients and physicians and using
its insight to identify, develop and commercialize leading-edge
medical dermatology products. The company’s approved treatment,
QBREXZA™ (glycopyrronium) cloth, is indicated for pediatric and
adult patients (ages 9 and older) with primary axillary
hyperhidrosis (excessive underarm sweating). Please see the QBREXZA
prescribing information. Dermira is evaluating lebrikizumab for the
treatment of moderate-to-severe atopic dermatitis (a severe form of
eczema) and plans to initiate a Phase 3 clinical development
program by the end of 2019, subject to an end-of-Phase 2 meeting
with the U.S. Food and Drug Administration. Dermira also has
early-stage research and development programs in other areas of
dermatology. Dermira is headquartered in Menlo Park,
Calif. For more information, please visit
http://www.dermira.com. Follow Dermira on Twitter, LinkedIn
and Instagram.
In addition to filings with the Securities and Exchange
Commission (SEC), press releases, public conference calls and
webcasts, Dermira uses its website (www.dermira.com),
LinkedIn page (https://www.linkedin.com/company/dermira-inc-),
corporate Instagram account
(https://www.instagram.com/dermira_inc/) and corporate Twitter
account (@DermiraInc) as channels of distribution of information
about its company, product candidates, planned financial and other
announcements, attendance at upcoming investor and industry
conferences and other matters. Such information may be deemed
material information and Dermira may use these channels
to comply with its disclosure obligations under Regulation FD.
Therefore, investors should monitor Dermira’s website, LinkedIn
page, Instagram and Twitter accounts in addition to following
its SEC filings, news releases, public conference calls
and webcasts.
Forward-Looking Statements
The information in this news release contains forward-looking
statements and information within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, which are subject to
the “safe harbor” created by those sections. This news release
contains forward-looking statements that involve substantial risks
and uncertainties, including statements with respect to Dermira’s
goal of bringing biotech ingenuity to medical dermatology by
delivering differentiated, new therapies to the millions of
patients living with chronic skin conditions and Dermira’s plans to
initiate a Phase 3 development program for lebrikizumab by the end
of 2019, subject to an end-of-Phase 2 meeting with the U.S. Food
and Drug Administration. These statements deal with future events
and involve known and unknown risks, uncertainties and other
factors that may cause actual results, performance or achievements
to be materially different from the information expressed or
implied by these forward-looking statements. Factors that could
cause actual results to differ materially include risks and
uncertainties such as those relating to Dermira’s dependence on
third-party clinical research organizations, manufacturers,
suppliers and distributors; the design and implementation of
Dermira’s clinical trials; the outcomes of future meetings with
regulatory agencies; Dermira’s ability to attract and retain key
employees; Dermira’s ability to manage the growth and complexity of
its organization; Dermira’s ability to maintain, protect and
enhance its intellectual property; and Dermira’s ability to
continue to stay in compliance with its material contractual
obligations, applicable laws and regulations. You should refer to
the section entitled “Risk Factors” set forth in Dermira’s Annual
Report on Form 10-K, Dermira’s Quarterly Reports on Form 10-Q and
other filings Dermira makes with the SEC from time
to time for a discussion of important factors that may cause actual
results to differ materially from those expressed or implied by
Dermira’s forward-looking statements. Furthermore, such
forward-looking statements speak only as of the date of this news
release. Dermira undertakes no obligation to publicly
update any forward-looking statements or reasons why actual results
might differ, whether as a result of new information, future events
or otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190430006103/en/
Media:Erica JeffersonVice President, Corporate
Communications650-421-7216media@dermira.com
Investors:Andrew GuggenhimeChief Financial
Officer650-421-7200investor@dermira.com
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Jul 2023 to Jul 2024